Publication: 4627

Publication: 4627

Association of SULT2A1 locus with abiraterone clearance in the Alliance A031201: Randomized phase III study of enzalutamide compared with enzalutamide plus abiraterone for metastatic castration-resistant prostate cancer

DOI

Google Scholar

Citation:: Clin Transl Sci vol 18 (12) 1752-8054

Year:: 2025
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 15

Parents:: 4412
Children:: None

Program:: TRP
Primary Committee:: PPP
Sec. Committees:

Pharmas:: Astellas; Pfizer
Grants:: U10CA180821, U10CA180882, U24CA196171, P30CA047904; P30 CA008748

Corr. Author:
Authors:: Nadine Norton Nicholas B. Larson Gregory D. Jenkins Jan H. Beumer Brooke Langevin Joga Gobbaru Michael J. Morris Yusuke Nakamura Deanna L. Kroetz Hao-Jie Zhu Peter H. O'Donnell Lionel D. Lewis Daniel L. Hertz

Networks:: CA824, LAPS-IL057, LAPS-MD017, LAPS-MI014, LAPS-MN026, LAPS-NH012, LAPS-NY016

Study: Alliance-A031201
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Pharmacogenomics, Pharmacokinetics, SULT2A1, Expression quantitative trait loci (eQTL), Prostate cancer